Success Metrics

Clinical Success Rate
100.0%

Based on 19 completed trials

Completion Rate
100%(19/19)
Active Trials
1(4%)
Results Posted
63%(12 trials)

Phase Distribution

Ph phase_2
7
28%
Ph phase_1
6
24%
Ph phase_3
7
28%
Ph phase_4
2
8%

Phase Distribution

6

Early Stage

7

Mid Stage

9

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
6(27.3%)
Phase 2Efficacy & side effects
7(31.8%)
Phase 3Large-scale testing
7(31.8%)
Phase 4Post-market surveillance
2(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.5%

19 of 21 finished

Non-Completion Rate

9.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

25

all time

Status Distribution
Active(1)
Completed(19)
Terminated(2)
Other(3)

Detailed Status

Completed19
unknown3
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (27.3%)
Phase 27 (31.8%)
Phase 37 (31.8%)
Phase 42 (9.1%)

Trials by Status

unknown312%
withdrawn28%
active_not_recruiting14%
completed1976%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT04669158Phase 1

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

Completed
NCT04534023Phase 2

A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies

Active Not Recruiting
NCT04152655Phase 2

A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease

Withdrawn
NCT00697073Phase 3

Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

Completed
NCT00537680Phase 3

Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia

Completed
NCT05931029

Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis

Completed
NCT03433807

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

Unknown
NCT02774005Phase 4

Study to Assess the Efficacy and Safety of Raxone in LHON Patients

Completed
NCT05411978Phase 4

Safety and Efficacy of Oral Idebenone for Preventive Treatment of Migraine in Adult Migraine Patients

Unknown
NCT02771379

Post Authorisation Safety Study With Raxone in LHON Patients

Completed
NCT01854359Phase 1

Idebenone for Primary Progressive Multiple Sclerosis

Completed
NCT04071639Phase 1

Symptomatic Therapy for Patients With Huntington's Disease

Unknown
NCT00950248Phase 1

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

Completed
NCT00229632Phase 2

Idebenone to Treat Friedreich's Ataxia

Completed
NCT00993967Phase 3

Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)

Completed
NCT00887562Phase 2

Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes

Completed
NCT00905268Phase 3

A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients

Completed
NCT01303406Phase 3

Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)

Completed
NCT01027884Phase 3

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

Completed
NCT01495715Phase 3

Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
25